nabu.science
MethodologyAboutContact

 

  • Snapshot
  • Key Claims
  • Strengths & Limitations
  • Commentary
  • From the Authors
  • Author Note / Field Feedback
  • Dimension breakdown
  • Impact Profile
Free · About 5 minutes
Report #NBU-CFD9164F·Framework v5.9·Pipeline v0.4·Evaluated 08 Oct 2026·OECD: 3.2 Clinical medicine·Subfield: Neurology·Basis: Full text·Type: Cross-sectional study

Repeat expansions in Parkinson's disease and parkinsonism across ancestries: insights from a global genetic cohort.

Lange et al.Lange, Cerquera-Cleves, Tan et al.·2026·medRxiv : the preprint server for health sciences·10.64898/2026.06.12.26354932 ↗

Primary claim

intermediate ATXN2 repeat expansions exhibited a strong, length-dependent association with PD risk in the European population, with individuals with ≥32 repeats having a more than four-fold increased risk

Supported · directionally consistent sparse-event association, limited by five controls, threshold scanning, and an unexplained analytic denominator
In brief

A valuable multi-ancestry map of repeat expansions in parkinsonism, constrained by unresolved reporting inconsistencies around its headline ATXN2 association.

ReliabilityConcerns4 of 4 checks completeRead the entry ↓
Fragile — the claim's weakest requirement is that the effect is as large as stated. Experimental. Every point below is traceable to a quoted passage, but this forecast has not yet been validated against known replication outcomes.
Abstract

Expanded short tandem repeats contribute to a broad spectrum of neurodegenerative diseases, yet their roles in Parkinson's disease (PD) and parkinsonism remain incompletely characterized, especially across diverse ancestries. We analyzed short-read whole-genome (WGS) and clinical exome sequencing (CES) data from 38,365 individuals (28,861 WGS; 9,504 CES), encompassing 23,242 patients with PD, 4,729 patients with atypical parkinsonism and 10,394 healthy controls from 11 genetic ancestries. To determine carrier frequencies and characterize repeat structures across diverse ancestries, we genotyped 12 established pathogenic loci where normal, intermediate, and pathogenic alleles can be reliably differentiated using short-read sequencing data. Additionally, we conducted threshold-based associations to determine the minimum threshold associated with increased PD risk in 15,995 individuals (8,591 PD, 7,404 controls) of European ancestry. Pathogenic repeat expansions were detected in 62 patients (56 PD and 6 atypical parkinsonism) and 5 controls across seven loci (AR, ATXN1, ATXN2, ATXN3, CACNA1A, HTT and THAP11), spanning seven ancestries. Among these, ATXN2 expansions were the most frequently observed in PD and were present in African, East Asian, European and Middle Eastern ancestries. Additionally, intermediate ATXN2 repeat expansions exhibited a strong, length-dependent association with PD risk in the European population, with individuals with ≥32 repeats having a more than four-fold increased risk (odds ratio 4.25, 95% confidence interval 1.80-12.05). Overall, >92% of expanded alleles harbor CAA interruptions within the CAG tract. Pathogenic expansions at other loci, such as ATXN3 and THAP11, showed more ancestry-specific distributions. Clinically, individuals with pathogenic ATXN2 and ATXN3 expansions most often presented with typical PD features but frequently showed earlier disease onset and a strong family history of PD. This large-scale, multi-ancestry study comprehensively maps the genetic landscape of pathogenic and intermediate repeat expansions in PD. Our findings confirm a length- and structure-dependent risk association for ATXN2 with PD in the European population and highlight the pleiotropic effects of repeat expansions across the parkinsonian spectrum.

Key Claims

Primary finding · Supported

intermediate ATXN2 repeat expansions exhibited a strong, length-dependent association with PD risk in the European population, with individuals with ≥32 repeats having a more than four-fold increased risk

Fragile — the claim's weakest requirement is that the effect is as large as stated. Experimental. Every point below is traceable to a quoted passage, but this forecast has not yet been validated against known replication outcomes.

directionally consistent sparse-event association, limited by five controls, threshold scanning, and an unexplained analytic denominator

Abstract; Results, Repeat-Length Disease Association Analyses
Quote verified
Secondary · Supported

Pathogenic repeat expansions were detected in 62 patients and 5 controls across seven loci, spanning seven ancestries.

WGS counts are directly enumerated, although additional CES carriers make the combined-cohort framing incomplete

Abstract; Results, Pathogenic Repeat Expansions in PD and Atypical Parkinsonism
Secondary · Well-supported

ATXN2 expansions were the most frequently observed in PD and were present in African, East Asian, European and Middle Eastern ancestries.

locus and ancestry counts directly support the ranking and four-ancestry occurrence

Abstract; Results, Pathogenic Repeat Expansions in PD and Atypical Parkinsonism
Quote verified
Secondary · Tentative

Overall, >92% of expanded alleles harbor CAA interruptions within the CAG tract.

92.7% applies to European carriers, while reported frequencies are lower in several other ancestries

Abstract; Results, Repeat Motif Structure in Expanded Alleles
Quote verified

Derived from the full evaluation — not a separate score.

Strengths · Limitations

Strengths

#contribution

Large multi-ancestry repeat-expansion map

The analysis spans 38,365 individuals, 12 repeat loci, and 11 genetic ancestries, providing a broader descriptive landscape than prior small or population-specific screens.

↳ Abstract; Methods, Study Design and Participants; Results, Pathogenic Repeat Expansions

#methodological rigour

Layered molecular validation workflow

Intermediate and pathogenic calls were visually reviewed, selected WGS calls underwent PCR or Sanger validation, ATXN3 calls received Nanopore confirmation, and WGS–CES concordance was assessed in 952 overlapping samples.

↳ Methods, Repeat Expansion Genotyping

#methodological rigour

Sparse-event analysis and multiplicity control

The threshold analysis used Firth penalized logistic regression and a study-wide Bonferroni threshold across 44 bins, while explicitly identifying instability at the highest ATXN2 cutoff.

↳ Methods, Repeat-Length Association with PD; Results, Repeat-Length Disease Association Analyses

Limitations

#reporting

Headline analysis denominators do not reconcile

The Abstract reports 15,995 European participants in the threshold analysis, whereas the Results report 14,720, leaving the final analytic denominator for the headline association unexplained.

↳ Abstract; Results, Repeat-Length Disease Association Analyses

#reporting

Central abstract claims exceed analyses

The reported “>92% overall” interruption rate corresponds only to European carriers, and structure-dependent risk is asserted without comparing interruption patterns between cases and controls.

↳ Abstract; Results, Repeat Motif Structure in Expanded Alleles

#methodological rigour

Association rests on sparse heterogeneous cohorts

The ≥32 ATXN2 estimate is based on 26 patients and five controls, while cases and controls include different source datasets and sequencing protocols that are not directly examined in the association model.

↳ Methods, Study Design and Participants and Repeat-Length Association with PD; Results, Repeat-Length Disease Association Analyses

Does this match your read? Add your assessment ↓

Nabu Commentary

The study’s principal value is its scale, multi-ancestry scope, and layered validation of short-read repeat calls. Its European ATXN2 analysis uses suitable sparse-event regression and multiplicity control, but the ≥32 estimate depends on only five controls and lacks replication. Reporting problems materially temper confidence: the Abstract and Results give different association denominators, and the claimed overall interruption frequency is not supported by the ancestry-stratified counts. The work therefore provides useful descriptive and hypothesis-strengthening evidence rather than a clinically actionable risk threshold.

Evaluate another paper

Free · About 5 minutes · Research preview

Author Note / Field Feedback

Nabu’s assessment, alongside the field’s view.

Are you an author of this paper?

Dimension breakdown

Evidence Score

Out of 5
012345
3.7±0.2

Contribution
4.0

The study meaningfully extends prior repeat-expansion work through a 12-locus, multi-ancestry screen and a European ATXN2 threshold analysis. The association partly confirms an existing signal, and several ancestry-specific observations rest on very small counts.

Introduction, paragraphs 2–3; Results, Pathogenic Repeat Expansions and Repeat-Length Disease Association Analyses

intermediate ATXN2 repeat expansions exhibited a strong, length-dependent association with PD risk in the European population

Methodological Rigour
3.5

The genotyping workflow includes visual review, PCR or Sanger validation, Nanopore confirmation for ATXN3, and WGS–CES concordance testing, while Firth regression addresses sparse cells. The key association nevertheless rests on five controls at the ≥32 threshold, and cohort-source selection and sequencing heterogeneity are not directly examined.

Methods, Repeat Expansion Genotyping and Repeat-Length Association with PD; Results, Repeat-Length Disease Association Analyses
Reporting
3.7

The paper follows a coherent sequence from genotyping through association, repeat structure, and clinical characterization. Reporting is reduced by the unsupported “>92% overall” statement and by concluding that risk is structure-dependent without a case-control test of interruption structure.

Abstract; Results, Repeat Motif Structure in Expanded Alleles; Discussion, final paragraph

Our findings confirm a length- and structure-dependent risk association for ATXN2 with PD

Positioning
3.8

The Introduction and Discussion engage the relevant ATXN2, ATXN3, CACNA1A, and THAP11 literature and trace several technical limitations to future work. They do not fully address case-control source differences, cohort ascertainment, or the fragility of the ≥32 estimate based on five controls.

Introduction, paragraphs 1–3; Discussion, paragraphs 1–8 and limitations paragraph

Lower confidence on Methodological Rigour — domain match limited.

Reliability

Concerns4 of 4 checks


Results checkConcern
  • intermediate ATXN2 repeat expansions exhibited a strong, length-dependent association with PD risk in the European population, with individuals with ≥32 repeats having a more than four-fold increased risk: "Additionally, we conducted threshold-based associations to determine the minimum threshold associated with increased PD risk in 15,995 individuals (8,591 PD, 7,404 controls) of European ancestry." (Abstract) vs "Using Firth’s penalized logistic regression adjusted for sex and the first five principal components in 7,963 European PD patients and 6,757 controls, we observed a significant association between expanded ATXN2 repeat length and PD risk across multiple length thresholds after Bonferroni correction for multiple testing (Figure 4; Supplementary Table 4). At a threshold of ≥32 repeats (26 patients, 5 controls), carriers had a more than four-fold increased risk of PD compared with non-carriers (odds ratio [OR] = 4.25, 95% CI: 1.80 to 12.05, P = 0.00057)." (Results, Repeat-length disease association analyses). The Results give 7,963 + 6,757 = 14,720 analyzed participants, 1,275 fewer than the abstract's 15,995, while explicitly reporting OR = 4.25 and P = 0.00057 for that smaller sample. → Conclusion holds
  • Overall, >92% of expanded alleles harbor CAA interruptions within the CAG tract: "Overall, >92% of expanded alleles harbor CAA interruptions within the CAG tract." (Abstract) vs "Among European carriers of expanded alleles (≥32 repeats) across phenotypes, 92.7% (38/41) contained one or more CAA interruptions within the CAG tract. The frequency of interruptions differed across ancestries, occurring in 76.5% (13/17) of EAS carriers and 66.7% (4/6) of AFR carriers. All expanded allele carriers of AAC (4/4), AMR (1/1), CAS (1/1) and MDE (1/1) ancestry also harbored at least one CAA interruption; however, these estimates should be interpreted cautiously given the limited sample sizes in non-European ancestries. Similarly, 88.5% (23/26) of ATXN2 expanded allele carriers identified from non-overlapping PD patients with CES data contained at least one CAA interruption." (Results, Repeat motif structure in expanded alleles). Pooling the reported ancestry counts gives (38 + 13 + 4 + 4 + 1 + 1 + 1)/(41 + 17 + 6 + 4 + 1 + 1 + 1) = 62/71 = 87.3%, or (62 + 23)/(71 + 26) = 85/97 = 87.6% when non-overlapping CES carriers are included. → Not supported by the paper's own data
  • Pathogenic repeat expansions were detected in 62 patients and 5 controls across seven loci, spanning seven ancestries: "Pathogenic repeat expansions were detected in 62 patients (56 PD and 6 atypical parkinsonism) and 5 controls across seven loci (AR, ATXN1, ATXN2, ATXN3, CACNA1A, HTT and THAP11), spanning seven ancestries." (Abstract) vs "Among the 9,504 non-overlapping PD patients with CES data (no genetic ancestry prediction available), pathogenic repeat expansions were identified in ATXN2 (n=6, 0.06%), CACNA1A (n=1, 0.01%) and AR (n=6, 0.06%)." (Results, Pathogenic repeat expansions in PD and atypical parkinsonism). The non-overlapping CES cohort adds 6 + 1 + 6 = 13 PD carriers to the abstract's 62 patients, giving 75 patients and 5 controls across the combined cohort. → Changes the size materially
Reporting and transparencyClean

No reporting or research-conduct concerns were raised for retention.

Conflict of interest: not stated · Ethics approval: declared · Preregistration: not stated · Data availability: declared · Code availability: declared

Reference IntegrityClean

57 references in manuscript 57 of 57 checkable references found in an index

References not verified automatically are resolved manually within 24 hours.

Post-Publication RecordClean

No retraction or expression of concern found in Crossref (includes Retraction Watch).

Last checked: 17 Oct 2026

Sources: Crossref (incl. Retraction Watch) ✓

Impact Profile

Impact areaHealth · Neurological · Parkinson's disease
Type of advanceEmpirical
Route to useNamed
AdvanceExtends
BeneficiariesMedium
CitationsToo early
Policy · patentNot yet traced
ReachedNot reachedNot assessable or unverified
ReadinessValidated
Foundational
Controlled
Piloted
Validated
Implementable
FoundationalImplementable

The primary association was tested in a large multi-cohort European case-control analysis of roughly 15,700 individuals using real-world genomic data from several sites, though not yet replicated in an independent study.

From the paper
“our results emphasize the importance of considering certain repeat expansions, i.e., ATXN2, ATXN3 and CACNA1A in the genetic evaluation of PD”

The conclusion names genetic evaluation of PD as the clinical setting in which these specific repeat expansions should be considered, implying neurologists and genetic services acting on the findings.

Pathway

Neurologists and genetic counselors could incorporate ATXN2 repeat genotyping into genetic evaluation of Parkinson's disease, guiding diagnosis and counseling for familial or early-onset cases.

Barrier

The intermediate-length risk association needs replication in independent, diverse cohorts, and the penetrance and clinical interpretation of intermediate ATXN2 alleles remain uncertain for testing decisions.

Evaluated 13 Nov 2026 · GBD 2023 · glm_v1_3_3 · impact_profile_v1_3_3

Report an issue →

AI-generated, human-governed. Something look off? Contact us to request a review.

Keep reading

Related evaluations

Other papers Nabu has evaluated blind, starting with the same field.

  1. Machine learning to diagnose, classify and predict phenoconversion in isolated REM sleep behavior disorder

    2026 · Clinical medicine

    Primary claim

    Overall, ML approaches show promise for scalable diagnosis and risk stratification in iRBD, but progress is constrained by methodological bias, inconsistent endpoints, data imbalance and a lack of explainable, externally validated models.

    Tentative
    Evidence Score
    3.0±0.2
    Reliability
    Caveats
  2. Single-molecule detection methods to study alpha-synuclein aggregation in postmortem Parkinson's disease brains

    Fertan, Danial, Neame, et al. · 2026 · Basic medicine

    Primary claim

    While aggregate numbers did not differ between PD and control samples, larger aggregates were detected in PD brain samples.

    Tentative
    Evidence Score
    3.0±0.2
    Reliability
    Caveats
  3. Gray Matter Microstructure Measured Using Diffusion Imaging as a Biomarker of Severity in Lewy Body Diseases

    Zarkali, Dobreva, Hannaway, et al. · 2026 · Clinical medicine

    Primary claim

    LBD showed widespread cortical and subcortical increases in free water fraction and, to lesser extent, orientation dispersion compared to controls and PD-NC, despite minimal atrophy and no neurite density differences.

    Supported
    Evidence Score
    3.8±0.2
    Reliability
    Caveats

How the rubric works →